Rapport Therapeutics Inc (RAPP) posted a Q4 2025 gaap loss of $0.72 per share, wider than the -$0.67 expected loss (6.8% wider). The clinical-stage biophar...
“Rapport Therapeutics Inc (RAPP) posted a Q4 2025 gaap loss of $0.72 per share, wider than the -$0.67 expected loss (6.8% wider). The clinical-stage biophar...
Newsdesk · March 11, 2026
Rapport Therapeutics Inc. (RAPP) posted a Q4 2025 GAAP loss of $0.72 per share, wider than the $0.57 per share loss reported in the year-ago quarter. The clinical-stage biopharmaceutical company focuses on developing small-molecule medicines for central nervous system disorders. The company did not report revenue as it does not have marketable products.
Rapport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
A detailed analysis of Rapport Therapeutics Inc’s quarter follows shortly on AlphaStreet. This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
